Successful Use of Recombinant Factor VIIa for Treatment of Severe Postpartum Hemorrhage | Citedby Results | American Journal of Critical Care | American Association of Critical-Care Nurses

Skip to Main Content

Skip Nav Destination

Successful Use of Recombinant Factor VIIa for Treatment of Severe Postpartum Hemorrhage

Am J Crit Care (2006) 15 (4): 399–401.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Emergency postpartum hysterectomy: incidence, trends, indications, and complications

Tomoyoshi Nohira
Takamoto Onodera
Keiichi Isaka

Hypertension Research in Pregnancy (2014) 2 (2): 88.

Utilisation hors AMM du facteur VII activé recombinant (Novoseven®) à l’AP–HP en 2010

J. Bardon
J. Fink
J. de Montblanc
J.-F. Bergmann
B. Sarrut
D. Benhamou

Annales Françaises d'Anesthésie et de Réanimation (2013) 32 (10): 659.

Recombinant activated factor VII (rFVIIa/NovoSeven®) in the management of severe postpartum haemorrhage: initial report of a multicentre case series in Japan

Takao Kobayashi
Masao Nakabayashi
Akira Yoshioka
Makoto Maeda
Tsuyomu Ikenoue

International Journal of Hematology (2012) 95 (1): 57.

Timely ′off-label′ use of recombinant activated factor VII (NovoSeven® ) can help in avoiding hysterectomy in intractable obstetric bleeding complicated with disseminated intravascular coagulation: A case report and review of the literature

Jyoti Burad
Pradipta Bhakta
Jasvinder Sharma

Indian Journal of Anaesthesia (2012) 56 (1): 69.

When the Pregnant Jehovah's Witness Patient Refuses Blood: Implications for Nurses

Pamela Braithwaite
Melanie Chichester
Adeyinka Reid

Nursing for Women's Health (2010) 14 (6): 462.

Successful management by recombinant activated factor VII in a case of disseminated intravascular coagulopathy caused by obstetric hemorrhage

Tomoyoshi Nohira
Yumi Osakabe
Shingo Suda
Chie Takahashi
Asashi Tanaka
Kazumi Ikeda
Toshiaki Ikeda
Kazuhiro Okabe

Journal of Obstetrics and Gynaecology Research (2008) 34 (4pt2): 623.